<DOC>
	<DOCNO>NCT02505087</DOCNO>
	<brief_summary>The objective study determine whether administration N-acetylcysteine ( NAC ) improve oxidative stress . To determine , study assess impact oral treatment balance reduce oxidized form glutathione erythrocytes peripheral blood .</brief_summary>
	<brief_title>Pharmacological Treatment Rare Genetic Disease : N-acetylcysteine Myopathy Associated Selenoprotein N-related Myopathy ( SEPN1-RM )</brief_title>
	<detailed_description>A prospective , monocentric , crossover , double-blind , placebo-controlled study . For patient study divide two treatment period 6 month separate 2 month washout period . 24 patient randomize two group , one group treat first placebo 6 month , follow 6 month ; second group treat reverse sequence , placebo . 24 healthy volunteer also enrol study order collect reference value biochemical biomarkers . D-1 : run-up visit , patient hospitalize intensive care unit collect information diet , physical activity smoking . During follow-up visit : analyze impact treatment N-acetylcysteine ( NAC ) : - Biomarkers redox homeostasis , - Measures locomotor functional capacity , - Body mass composition , - Respiratory functional ability . Biomarkers reflect status antioxidant defense mechanism , parameter reflect cell damage oxidative stress , marker inflammation metabolic alteration induce oxidative stress , body composition term lean mass fat mass , motor functional ability , respiratory function capability , compare treatment . These measure could complement information status oxidative stress clarify effect N-acetylcysteine ( NAC ) evolution disease patient . The correlation biomarker measurement muscle systemic tissue check . Furthermore collect information lifestyle standardize questionnaire include diet , smoking , habitual physical activity . Environmental factor lifestyle influence balance oxidant / antioxidant patient contribute variability clinical severity disease .</detailed_description>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1 . For patient : Patient &gt; 18 &lt; 60 year old Patients Selenoprotein Nrelated myopathy homozygous compound heterozygous mutation gene SEPN1RM Informed write consent Patients capable follow throughout duration study Patient train use cough assist Patients health insurance Patient accept commit introduce major change diet lifestyle study period 2 . For healthy volunteer : volunteer &gt; 18 &lt; 60 year old Informed write consent Health insurance 1 . For patient : Pregnancy Intolerance Nacetylcysteine ( NAC ) , galactose fructose ; malabsorption glucose galactose ; lactase deficiency Consumption synthetic vitamin , NAC antioxidant within 3 month prior inclusion Treatment corticosteroid nonsteroidal antiinflammatory time time 4 week precede inclusion 3 day 12 4 week inclusion Planned surgery within 3 month inclusion inclusion period Intercurrent exist illness chronic infectious disease ( HIV , hepatitis , etc . ) , asthma , malignant tumor pathology , Hematological Pathology Expected survival le 14 month Inability understand instruction implication Protocol 2 . For healthy volunteer : Pregnancy Consumption synthetic vitamin , NAC antioxidant within 3 month prior inclusion Treatment corticosteroid nonsteroidal antiinflammatory time time 4 week precede inclusion 3 day 12 4 week inclusion Planned surgery within 3 month inclusion inclusion period Intercurrent exist illness chronic infectious disease ( HIV , hepatitis , etc . ) , asthma , malignant tumor pathology , Hematological Pathology Inability understand instruction implication Protocol Bleeding disorder bleed risk risk infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Selenoprotein N-related myopathy</keyword>
	<keyword>biomarkers</keyword>
	<keyword>washout</keyword>
	<keyword>N-ACETYLCYSTEINE</keyword>
</DOC>